BREAKING: HRSA Now Says it Will Let Some Providers Enroll in 340B Immediately During COVID-19 Pandemic
The Health Resources and Services Administration (HRSA) has announced that, in
…Category: Breaking
BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts
The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts
…Breaking News
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of
…Breaking News
BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility
BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility
The Health Resources and Services Administration’s (HRSA) oversight of 340B private, nonprofit hospitals should be significantly strengthened, the Government Accountability Office (GAO) found in a report released
…Breaking News
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts
…BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus
The Health Resources and Services Administration (HRSA) announced this morning that it has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process.
“The 340B Prime Vendor
…Breaking News
BREAKING: Drugmaker Xspire Owes 340B Refunds
Greetings
Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.
BREAKING: Drugmaker Xspire Owes 340B Refunds
Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds
…